ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The small-molecule-drug services firm Cambrex will double the size of its solid-form screening and crystallization process development facility in Edinburgh, Scotland. To be completed by year-end, the project will allow Cambrex to add up to 40 more scientists to its 50 employees at the site. Cambrex acquired the facility with its purchase of Avista Pharma Solutions earlier this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter